Kim CA, et al. - Whether an improvement in disease-related symptoms, and therefore, a clinical benefit, while on chemotherapy is a predictive marker in advanced pancreatic cancer (APC), was investigated in this study including patients 18 and older with APC diagnosed between January 1, 2005 and December 31, 2010 and treated at the Cross Cancer Institute. Pain (80%), opioid use (61%), or weight loss (71%) was reported by most of the patients at baseline. With treatment, a clinical benefit was obvious in 34% patients but only 17% of these patients experienced a radiologic response. They reported improved progression-free survival (PFS) and overall survival (OS) in relation to experiencing a clinical benefit in patients with APC treated with chemotherapy. However, it did not appear to correlate with radiologic response to chemotherapy.